Compare ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund vs SBI Healthcare Opportunities Fund
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund
SBI Healthcare Opportunities Fund
Risk
Very High
Very High
Rating
5.0
5.0
Min SIP Amount
₹100
₹500
Expense Ratio
2.09
2
NAV
₹47.50
₹591.63
Fund Started
25 Jun 2018
04 Jun 1999
Fund Size
₹6624.58 Cr
₹4997.72 Cr
Exit Load
Exit load of 1% if redeemed within 15 days.
Exit load of 0.50% if redeemed within 15 days
1 Year
5.43%
15.09%
3 Year
23.11%
22.88%
5 Year
15.81%
16.87%
Equity
96.05%
97.16%
Cash
3.95%
2.78%
Top 10 Holdings
Sun Pharmaceutical Industries Ltd. | 12.20% |
Dr. Reddy's Laboratories Ltd. | 8.22% |
Mankind Pharma Ltd. | 6.98% |
Cipla Ltd. | 6.67% |
Alkem Laboratories Ltd. | 5.67% |
Divi's Laboratories Ltd. | 5.57% |
Cohance Lifesciences Ltd. | 4.31% |
Medplus Health Services Ltd. | 3.66% |
Max Healthcare Institute Ltd. | 3.10% |
Syngene International Ltd. | 2.89% |
Sun Pharmaceutical Industries Ltd. | 11.18% |
Acutaas Chemicals Ltd. | 6.35% |
Divi's Laboratories Ltd. | 5.92% |
Apollo Hospitals Enterprise Ltd. | 5.21% |
Max Healthcare Institute Ltd. | 5.08% |
Aurobindo Pharma Ltd. | 4.17% |
Aster DM Healthcare Ltd. | 3.77% |
Laurus Labs Ltd. | 3.64% |
Cipla Ltd. | 3.52% |
Torrent Pharmaceuticals Ltd. | 3.33% |
Name
-
-
Start Date
-
-
Description
The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies.
The scheme seeks to provide the investors with the opportunity of long-term capital appreciation by investing in a diversified portfolio of equity and equity related securities in Healthcare space.
Launch Date
25 Jun 2018
04 Jun 1999
